Dent Neurologic



The purpose of this study is to determine the efficacy of frexalimab in delaying the disability progression and the safety in participants with non-relapsing secondary progressive multiple sclerosis.

Inclusion Criteria:

  • 18-60 years of age, a diagnosis of non-relapsing secondary progressive multiple sclerosis
  • Stable immunomodulatory treatment
  • Diagnosed within the last 10 years, without clinical MS relapse or treatment with corticosteroids within last 6 months

What to Expect

Patients will be randomized to receive intravenous frexalimab or placebo up to approximately 51 months administration. A placebo looks like the study drug but contains no real medicine.

For more information click the link below or contact Allison Clarke at or 716-558-3543

Scroll to Top